Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The latest update is out from Artiva Biotherapeutics, Inc. ( (ARTV) ).
On May 8, 2026, Artiva Biotherapeutics, Inc. entered into an underwriting agreement with a syndicate of investment banks to issue 23,871,526 shares of common stock at $11.52 per share. The company also agreed to sell pre-funded warrants to purchase 2,170,138 shares at $11.5199 per warrant under an effective shelf registration with the Securities and Exchange Commission.
All securities in the offering were sold by Artiva, which expects gross proceeds of about $300 million before underwriting discounts and expenses, with closing targeted for May 11, 2026, subject to customary conditions. The pre-funded warrants are immediately exercisable but include ownership caps and adjustable beneficial ownership limits, illustrating a capital-raising structure designed to attract institutional investors while managing concentration and regulatory constraints for existing and new shareholders.
The most recent analyst rating on (ARTV) stock is a Buy with a $35.00 price target. To see the full list of analyst forecasts on Artiva Biotherapeutics, Inc. stock, see the ARTV Stock Forecast page.
Spark’s Take on ARTV Stock
According to Spark, TipRanks’ AI Analyst, ARTV is a Neutral.
The score is held back primarily by weak financial performance—widening losses and ongoing, sizable cash burn—despite modest leverage. Technicals are a key offset, with the stock in a strong uptrend and supportive momentum. Valuation provides limited support due to negative earnings and no dividend, while recent corporate events are encouraging on clinical progress and Phase 3 alignment.
To see Spark’s full report on ARTV stock, click here.
More about Artiva Biotherapeutics, Inc.
Artiva Biotherapeutics, Inc. is a biotechnology company focused on developing therapeutic products, operating within the broader life sciences and biopharmaceutical industry. The company accesses capital markets to fund its research, development and corporate activities through registered offerings of common stock and related securities.
Average Trading Volume: 230,882
Technical Sentiment Signal: Buy
Current Market Cap: $309.5M
For an in-depth examination of ARTV stock, go to TipRanks’ Overview page.